Transplanting stool from a healthy donor sounds like the kind of treatment that only exists in sensationalist headlines, but it’s a real therapy, already approved for certain intestinal infections, and in recent years it has started being tested against much more unexpected diseases, Parkinson’s among them. A new meta-analysis, published in the journal Revista de Neurología, has reviewed all the scientific evidence available so far on this idea. And the result calls for caution.
Why would anyone think of transplanting stool to treat Parkinson’s? The connection isn’t as far-fetched as it sounds. There’s growing evidence that Parkinson’s is linked to the so-called gut-brain axis, the constant communication between the bacteria living in our gut and the nervous system. People with Parkinson’s tend to have a different gut microbiota than the rest of the population, with fewer beneficial bacteria and more inflammation. That’s where the idea came from that replenishing those good bacteria through a fecal transplant (taking stool from a healthy donor and transplanting it into the patient’s gut) might slow or improve the disease’s symptoms.
What exactly this study analyzed. A team of researchers at Loudi Central Hospital, in China, systematically reviewed, following the international PRISMA protocol and with prior registration in the PROSPERO database, every randomized clinical trial published through September 2025 that tested fecal transplants in Parkinson’s patients. They found only five trials that met the necessary quality criteria, covering 226 participants in total: 119 received the real transplant and 107 a placebo or standard care.
The results show no significant improvement. Researchers measured motor symptoms, activities of daily living, and cognitive abilities using standard medical scales (the MDS-UPDRS for motor symptoms, and the MoCA and MMSE tests for cognitive function). In none of these areas, at 4, 12 or 24 weeks of follow-up, did the group that received the fecal transplant improve in a statistically significant way compared with the control group.
There’s one nuance worth flagging. In the activities-of-daily-living score at 12 weeks, transplanted patients showed a trend toward improvement that brushed against, without crossing, the usual threshold for statistical significance. The authors themselves describe it as a result that invites cautious optimism, not proof that the treatment works.
This doesn’t mean fecal transplants are a failure. The authors stress that these negative results likely reflect how early-stage this field of research still is, not that the idea itself has no future. Only five trials exist, with small samples, very different protocols from one another (some used frozen stool and others fresh, some administered it via colonoscopy and others in capsules), and follow-up periods too short to detect changes that might take longer to appear. What is clear is that the procedure proved safe for patients.
What this means for the average reader. If you’ve seen fecal transplants touted as a possible miracle cure for Parkinson’s on social media, this scientific review is a good reminder of how science actually works: with caution, without shortcuts, and without getting swept up in enthusiasm ahead of time. For now, the available evidence doesn’t support its use as an effective treatment for Parkinson’s symptoms, though it doesn’t rule it out entirely either. Larger trials with longer follow-up are needed to know whether this therapy really has something to offer.
About this article. This piece is based on the scientific study “Systematic Review and Meta-Analysis of the Efficacy of Fecal Microbiota Transplantation in Parkinson’s Disease: An Exploration Based on UPDRS and Cognitive Scores,” by Benyao Liang and his team at Loudi Central Hospital (China), published on June 26, 2026 in the journal Revista de Neurología, open access under a CC BY 4.0 license. DOI: 10.31083/RN50106.
